Technology | Breast Imaging | October 02, 2015

Hologic Highlighting Breast Tomosynthesis at RSNA 2015

Product offerings will focus on 3-D mammography, breast biopsy systems

Hologic, RSNA 2015, breast tomosynthesis, breast biopsy systems

I-View contrast enhanced 2-D mammography image courtesy of Hologic

October 2, 2015 — At the Radiological Society of North America’s (RSNA) 2015 annual meeting, Hologic will emphasize its breast tomosynthesis offerings across multiple product lines.

The company expects to see continued interest in the field, as a recent survey of U.S. mammography providers by KLAS Research found 65 percent of respondents planned to invest in breast tomosynthesis technology during the next two years, up from 57 percent in 2014.

Hologic’s featured products will include:  

Genius 3D Mammography exams

Available on Hologic’s Selenia Dimensions system, Genius 3D Mammography exams help find breast cancers earlier, while reducing recall rates and false positives.

C-View-generated 2-D images from a Selenia Dimensions breast tomosynthesis dataset

The C-View software is designed to generate 2-D images from Genius 3D Mammography image slices, eliminating the need for a separate 2-D exposure during a 3-D exam. C-View technology is designed to offer radiologists and patients a number of benefits including a reduction in X-ray exposures leading to shorter exam times (less than 4 second scan per view), and increased patient comfort from the shorter compression time.

Affirm Breast Biopsy Guidance System for Selenia Dimensions

The Affirm 3-D breast biopsy technology is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions found with the Genius 3D Mammography exam. The Affirm system is designed to accelerate and simplify the biopsy workflow compared with previous stereotactic biopsy procedures.

I-View contrast enhanced 2-D mammography and tomosynthesis fusion

Using an iodinated contrast agent, I-View software on the Selenia Dimensions system enables users to image the functional 2-D contrast uptake and the morphological Genius 3D Mammography image in rapid sequence and combine these two image sets into a single fused study. In the fused study, the 2-D contrast image can identify potential lesions based on their physiological state due to an increase in the contrast agent uptake. The 3-D image can then be overlaid on the 2-D contrast image and provide morphological information on the lesion, such as improved visibility of associated spiculations.

I-View dual modality contrast-enhanced imaging is designed to confirm findings and localize lesions when breast cancer imaging results are inconclusive. A contrast enhanced exam using the software can be performed in less than 10 minutes, in the same exam room and on the same screening equipment.

The I-View imaging mode is designed to offer several advantages over conventional contrast breast magnetic resonance imaging (MRI):

  • Reduced cost;
  • Contrast imaging availability to patients for whom MRI is contraindicated; and
  • Access to patients in areas where MRI systems are not available.

I-View imaging software is an extension of the existing indication for diagnostic imaging with the Selenia Dimensions system. The product is U.S. Food and Drug Administration (FDA) 510(k) cleared and CE marked.

Quantra breast density assessment software for breast tomosynthesis

Quantra v2.1 software is FDA-cleared and compatible for breast tomosynthesis. It features the latest advances in density assessment algorithms, a newly designed and easy to read Secondary Capture display using BI-RADS 5th edition terminology, and user-friendly naming for all Quantra assessed values.

In addition to their tomosynthesis offerings, Hologic will also display other products including:

Sertera biopsy device, the newest member of Hologic’s ultrasound-guided breast biopsy family. The device is a disposable, core needle biopsy device available in multiple gauge sizes; it is lightweight and designed to be completely armed and fired with one hand.

Brevera breast biopsy system with CorLumina imaging technology. An advanced biopsy platform designed to increase clinical confidence and reduce procedure times.

New prone biopsy system. The system is a fully redesigned dedicated prone biopsy solution. The prone table uses the latest mammography imaging technology including 3-D imaging. It is designed to make it fast and easy to identify and confidently target lesions, especially those found using the Genius 3D Mammography exam.

For more information: www.hologic.com

Related Content

Fluke Biomedical Introduces RaySafe 452 Survey Meter
Technology | Radiation Dose Management | July 11, 2019
Radiation measurement often requires different devices for varying applications, adding to the cost and complexity of...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Infervision Releases InferTEST Program at SIIM 2019
News | Artificial Intelligence | July 08, 2019
Infervision announced their InferTEST program at the recent Society for Imaging Informatics in Medicine (SIIM)...
Hyland Healthcare Adds ImageNext Imaging Workflow Optimizer to Enterprise Imaging Suite
Technology | Enterprise Imaging | July 05, 2019
Hyland Healthcare is launching ImageNext, a vendor-neutral imaging workflow optimizer that combines intelligent imaging...
TeraRecon Unveils iNtuition AI Data Extractor
News | Advanced Visualization | July 03, 2019
Artificial Intelligence (AI) and advanced visualization company TeraRecon announced its new iNtuition AI Data Extractor...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

GE Healthcare showcases Senographe Pristina Serena featuring its add-on-biopsy kit at the Breast Imaging Symposium. Photo by Greg Freiherr

Feature | Breast Imaging | July 03, 2019 | By Greg Freiherr
Productivity and its enabler — efficiency — guided the display of products at the April...
Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine
Feature | Women's Health | July 03, 2019 | By Samir Parikh
Contrary to what many people believe,...